<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579900</url>
  </required_header>
  <id_info>
    <org_study_id>CMI2 CHU</org_study_id>
    <nct_id>NCT04579900</nct_id>
  </id_info>
  <brief_title>Dissecting Host-microbiome Modifiers of Type 2 Diabetes Risk</brief_title>
  <acronym>DBBIOTE</acronym>
  <official_title>Dissecting Host-microbiome Modifiers of Type 2 Diabetes Risk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laval University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laval University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is now well documented that changes in gut microbiota composition accompany obesity and&#xD;
      type 2 diabetes (T2D) and contribute to low-grade inflammation, insulin resistance,and&#xD;
      glucose intolerance. It is not yet clear if T2D predisposes the intestine to allow more&#xD;
      microbial products or possibly live bacteria to subvert the gut mucosal barrier. However, it&#xD;
      is known that hyperglycemia during T2D induces a more permissive gut barrier allowing&#xD;
      increased penetration of microbes and their products into the blood. An important next step&#xD;
      is to determine which strains of bacteria promote dysbiosis, allowing bacteria or bacterial&#xD;
      components to subvert the gut barrier and alter glucose control. It is hypothesized that gut&#xD;
      microbes in the colon and other lower gut segments are key modulators of energy balance,&#xD;
      glucose homeostasis and insulin sensitivity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The gut acts as a barrier to bacteria and nutrients and participates in glucose homeostasis&#xD;
      via endocrine actors and the gut-brain-peripheral axis. It is unclear how T2D alters microbes&#xD;
      in upper and lower intestine of humans. Studies in animals show that T2D promotes&#xD;
      translocation of microbes to the blood and tissues to promote metabolic dysfunction. It is&#xD;
      crucial to determine whether bacteria or their components subvert the gut barrier in human&#xD;
      T2D, and then to identity the relevant bacterial strains in tissues that control blood&#xD;
      glucose. The overall objective of our research program is to demonstrate that specific&#xD;
      microbes in the gut, circulation, and key metabolic tissues are involved in the progression&#xD;
      of T2D. We will define the microbial signatures of T2D in duodenal biopsies and stool samples&#xD;
      by comparing T2D and non-T2D subjects.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbial signature</measure>
    <time_frame>One week</time_frame>
    <description>Compare the bacterial profile of T2D and non-T2D subjects</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Type 2 Diabetes patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upper gut biopsies and lower gut samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non Type 2 Diabetes patients</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Upper gut biopsies and lower gut samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endoscopy and duodenal biopsy and sampling</intervention_name>
    <description>All volunteers will have endoscopy and duodenal biopsy and will have to provide stool samples</description>
    <arm_group_label>Non Type 2 Diabetes patients</arm_group_label>
    <arm_group_label>Type 2 Diabetes patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T2DB de novo or non T2DB patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  oral hypoglycemic agents or lipidlowering or antihypertensive drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>André Marette, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laval University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Geneviève Pilon, PhD</last_name>
    <phone>418-656-8711</phone>
    <phone_ext>3783</phone_ext>
    <email>Genevieve.Pilon@criucpq.ulaval.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>INAF, Université Laval</name>
      <address>
        <city>Québec</city>
        <zip>G1V 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>André Tremblay, Ph.D</last_name>
      <phone>1-418-656-2131</phone>
      <phone_ext>411417</phone_ext>
      <email>andre.tremblay@fsaa.ulaval.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 6, 2020</study_first_submitted>
  <study_first_submitted_qc>October 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>February 16, 2021</last_update_submitted>
  <last_update_submitted_qc>February 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Laval University</investigator_affiliation>
    <investigator_full_name>André Marette</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

